Relapsed B-Cell Acute Lymphoblastic Leukemia Clinical Trial
Official title:
A Phase I Trial of T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
The purpose of this study is to test the safety of giving the patient special cells made from their own blood called "Modified T-cells". The goal is to find a safe dose of modified T-cells for patients whose leukemia has returned to the bone marrow.
This is a phase I multicenter clinical trial for pediatric and young adult patients with relapsed/refractory CD19+ B-ALL. The T cell doses originally proposed in this study were based on doses administered safely in prior T cell adoptive therapy trials, but the dose has been modified based on the toxicities observed in adult patients with morphologic evidence of relapsed B-ALL treated on MSKCC IRB 09-114. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03156101 -
A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects
|
Phase 1/Phase 2 | |
| Completed |
NCT02808442 -
Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia
|
Phase 1 | |
| Withdrawn |
NCT02167360 -
Study of Efficacy and Safety of CTL019 in Adult ALL Patients
|
Phase 2 | |
| Recruiting |
NCT04556084 -
Blinatumomab Bridging Therapy
|
Phase 2 | |
| Recruiting |
NCT06179524 -
CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
|
Phase 2 | |
| Completed |
NCT02228096 -
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
|
Phase 2 |